Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020
Authors:
- 4 January 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (1) , e2035064
Abstract
Several new medications for treating common chronic conditions have come to market in the US in recent years. While such increased competition might be expected to decrease drug prices, policies promoting competition among brand-name drugs within the same class have not been associated with lower list prices.1 In fact, an analysis of the wholesale acquisition costs of insulins from 2012 to 2016, when only branded formulations were available, demonstrated compound annual growth rates (CAGRs) in costs ranging from 15% to 17%.2 The objective of this cross-sectional study was to assess patterns in price changes for multiple brand-name medications within the same drug class existing in the US market contemporaneously.Keywords
This publication has 3 references indexed in Scilit:
- Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018JAMA, 2020
- Competition and price among brand-name drugs in the same class: A systematic review of the evidencePLOS Medicine, 2019
- Insulin Access and Affordability Working Group: Conclusions and RecommendationsDiabetes Care, 2018